Kyle Busse, PhD, MPH
Postdoctoral Researcher, Epidemiology Division
Dr. Kyle Busse is a nutritional and reproductive epidemiologist whose research focuses on fertility and adverse pregnancy outcomes. He is particularly interested in the application of causal inference methods for understanding how modifiable lifestyle factors, like diet, affect reproductive and perinatal health. He also has a strong interest in the methodological challenges of measuring dietary intake for large-scale studies.
Research Areas
Causal Inference, Large-Scale Cohorts, Life Course Epi, Etiology of Population Health
Education
- PhD in Nutrition, University of North Carolina-Chapel Hill 2024
- MPH in Global Health Epidemiology, University of Michigan 2019
- BA in Spanish and BS in International Health, Bethel College 2017
Contact
Email:Â kyle.busse@pennmedicine.upenn.edu
🎓 Google Scholar
Research Highlights
Environmental Influences on Child Health Outcomes (ECHO)
Overview: Researchers from the University of Pennsylvania (UPenn) and the Children’s Hospital of Philadelphia (CHOP) have joined together to support a National Institutes of Health (NIH) program called Environmental influences on Child Health Outcomes (ECHO). This large, observational child health research study began in 2016 to try to answer big questions about how influences in early human development, even before birth, affect us throughout our lives and across generations. The ECHO program is focused on five areas of children’s health: pregnancy and birth, breathing, body weight, brain development, and well-being. By enrolling 2500 pregnant individuals and their children from diverse backgrounds (racially, ethnically, and socioeconomically), the Penn-CHOP research team will help contribute to the understanding and enhancement of children for generations to come.
How Do Common Treatments Affect Heart Health in Women with Polycystic Ovary Syndrome?
Overview: Women with polycystic ovary syndrome (PCOS), which is among the most common gynecologic conditions in the world, are more likely to experience poor cardiovascular health than women who do not have the condition. First-line treatments for PCOS include oral contraceptive pills and metformin. However, the effect of these treatments on the cardiovascular health of women with PCOS remains unclear. In this project, investigators from the University of Pennsylvania are using data from health insurance claims and target trial emulation – a novel causal inference method – to examine the effects of oral contraceptive pills and metformin, alone and in combination, on the risk of atherosclerotic cardiovascular disease in women with PCOS.